Search for a trial

A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study
of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent
Glioblastoma (GBM)

This study will investigate whether treatment with Nivolumab is comparable to Bevacizumab in patients with Glioblastoma. We will measure this by comparing how many patients arestill alive after a certain period of time once they have started…

An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator*s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer

The study will look at patients with advanced Non-Small Cell Lung Cancer (NSCLC) whose tumours express a certain type of protein called PD-L1. The research aims to compare a new drug called nivolumab against Investigator's choice of…

An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's
Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head
and Neck (SCCHN)

The study will look at patients with Squamous Cell Head and Neck Cancer (SCCHN) whose tumours express a certain type of protein called PD-L1. The research aims to compare a new drug called nivolumab against Investigator's choice of chemotherapy…

A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects with
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous
Stem Cell Transplant (ASCT) or After Failure of At Least Two Prior Multi-Agent Chemotherapy
Regimens in Subjects Who Are Not Candidates for ASCT

Research Hypothesis: Treatment with nivolumab (BMS-936558) will lead to clinical benefit, as demonstrated by a clinically meaningful objective response rate, including durable responses with substantial magnitude of tumor burden reduction.Primary…

An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Primary ObjectiveTo compare the objective response rate and overall surival of BMS-936558 versus docetaxel in subjects with squamous cell NSCLC after failure of prior platinum-based chemotherapySecondary ObjectivesTo compare the progression-free…

A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study

Primary Objective* To determine the DCR (disease control rate) at 12 weeks of nivolumab monotherapy in patients with progressive MPM.Secondary Objectives* To determine the safety of nivolumab monotherapy in patients with progressive MPM* To…

A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination
with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma.

This study will investigate whether treatment with Nivolumab in combination with radiation therapy, is comparable to Temozolomide in combination with radiation therapy in patients with Unmethylated MGMT Glioblastoma. We will measure this by…

A randomized phase 2 single blind study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in newly diagnosed adult subjects with MGMT-Methylated (tumour 06-methylguanine DNA methyltransferase) Glioblastoma.

To compare PFS of subjects with newly-diagnosed MGMT methylated or indeterminate GBM subtypes treated with RT plus TMZ combined with nivolumab or placebo. PFS will be determined by BICR based on RANO criteria.To compare OS of subjects with newly-…